[6-K] Barclays PLC Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Form 4 filing for AnaptysBio, Inc. (ANAB) dated 07/03/2025 discloses that director Hollings Renton executed expiring stock options and immediately sold most of the resulting shares under a pre-arranged Rule 10b5-1 trading plan.

• Option exercise: 20,925 options were exercised at an exercise price of $6.93 (grant dated 07/06/2015, expiring 07/05/2025).
• Share sales: • 7,250 shares sold at a weighted-average $23.0908 • 13,675 shares sold at a weighted-average $23.8232. The weighted-average sale ranges were $22.425–$23.395 and $23.56–$24.015, respectively.
• Post-transaction holdings: Direct common-stock ownership declined from 25,890 to 4,965 shares. The insider retains ≥112,051 additional option shares that vest per their original schedules.
• The trades were executed pursuant to a Rule 10b5-1 plan adopted on 03/14/2024, signalling pre-planned, non-discretionary activity ahead of the 07/05/2025 option expiration.

The filing represents routine expiration-driven option exercise coupled with partial monetisation. While the insider’s direct share count fell by roughly 81%, his large remaining option position maintains exposure to future upside. No company operational or financial metrics are included; the disclosure is limited to insider ownership changes.

Positive

• Director retains economic exposure through at least 112,051 unexercised option shares, indicating continued alignment with shareholder interests.

Negative

• Direct common-stock holdings decreased by approximately 81% (from 25,890 to 4,965 shares), which some investors may interpret as reduced insider confidence.

Insights

Securities Analyst

TL;DR Routine option exercise; director sells ~81% of new shares, retains large option pool—mildly negative signalling but limited overall impact.

The transaction appears largely mechanical: options granted in 2015 were within days of expiry, obligating exercise or forfeiture. Mr. Renton exercised 20,925 shares at $6.93 and liquidated 20,925 – 4,965 = 15,960 shares at ~$23, crystallising an immediate spread of roughly $16 per share (≈$0.34 M before taxes). Direct ownership shrank, which can be perceived as a modestly bearish signal, yet the sale was governed by a 10b5-1 plan. Importantly, the insider still holds over 112 K option shares, preserving economic alignment with shareholders. Given ANAB’s average daily volume and the small absolute share count, I categorise the market impact as not impactful and assign a rating of 0 (neutral).

Corporate Governance Expert

TL;DR Pre-planned 10b5-1 trades reduce optics of insider selling risk; governance compliance looks sound.

The filing follows good governance practice: (1) use of a 10b5-1 plan, adopted well before execution, (2) full price-range disclosure, and (3) clear footnotes on remaining awards. From a governance perspective, the exercise-and-sell sequence prevents option expiration while avoiding open-window timing concerns. Although the insider’s direct stake is smaller, his unvested/vested options keep him properly incentivised. I deem the event non-material for governance risk and assign a neutral impact rating.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of July, 2025

Commission File Number: 001-09246

Barclays PLC

(Name of Registrant)

1 Churchill Place
London E14 5HP
England
(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F ☐

The Report comprises the following:

Exhibit No.		Description
Exhibit 99.1		Barclays PLC provides a notice of redemption and cancellation of listing to the holders of Barclays PLC’s $1,500,000,000 5.304% Fixed Rate Resetting Senior Callable Notes due 2026, dated July 3, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BARCLAYS PLC
	(Registrant)
Date: July 3, 2025	By:	/s/ Garth Wright
	Name:	Garth Wright
	Title:	Assistant Secretary

FAQ

How many AnaptysBio (ANAB) shares did the director sell?

Hollings Renton sold 7,250 shares at ~$23.09 and 13,675 shares at ~$23.82, totalling 20,925 shares on 07/02/2025.

What was the exercise price of the options in AnaptysBio's Form 4?

The options were exercised at an exercise price of $6.93 per share.

Does the insider still hold AnaptysBio stock options after the sale?

Yes. Footnote 5 states the insider holds additional options for 112,051 shares that vest according to their terms.

Was the AnaptysBio insider sale under a 10b5-1 plan?

Yes. The Form 4 confirms the sales were executed under a Rule 10b5-1 plan adopted on 03/14/2024.

What is the remaining direct share ownership of the AnaptysBio director?

After the transactions, the director directly owns 4,965 shares of ANAB common stock.